2008 Jun;25(6):1412-9 (particularly any one of those described in Table I of this reference), any one of the modified amino acids disclosed in US 5,866,536 (particularly any one of compounds I to CXXIII, as disclosed in US 5,866,536 which is incorporated herein by reference, or a pharmaceutically acceptable salt or solvate thereof, such as a disodium salt, an ethanol solvate, or a hydrate of any one of these compounds), any one of the modified amino acids disclosed in US 5,773,647 (particularly any one of compounds 1 to 193, as disclosed in US 5,773,647 which is incorporated herein by reference, or a pharmaceutically acceptable salt or solvate thereof, such as a disodium salt, an ethanol solvate, or a hydrate of any one of these compounds), any of the nanoparticles described in WO 2011/133198, any of the polymer preparations described in US 2015/174076 and/or a hydrogel (e.g., as described in Torres-Lugo M et al

Jimmy wrote a letter of complaint and quoted NICE, BNF (British National Formulary) and the NHS website and pled his case to receive proper care
At present, a majority of studies examined the effect of conductive CNT-containing scaffolds only in vitro on different cells such as PC12 or SCs [8, 42, 57]
Researchers first characterised the peptide in the early 1990s, and its since built up one of the most extensive bodies of preclinical literature in the field